PURIFIED PROTEINS

IPC classification:

A61K 38/20, C07K 14/545, B01D 15/36

Agent:

Multiple attorneys, Mathys & Squire LLP

Status:

█ APPLICATION DEEMED TO BE WITHDRAWN

Genz 112638 for treating Gaucher or Fabry disease in combination therapy

IPC classification:

A61K 31/4025, C07D 405/06, A61P 35/00

Applicant:

Genzyme Corporation

Agent:

Stephen Garner, Mathys & Squire LLP

Agent:

Potter Clarkson LLP

Status:

█ NO OPPOSITION FILED WITHIN TIMELIMIT

COMPOSITIONS AND METHODS FOR TRANSMUCOSAL ABSORPTION

IPC classification:

A61K 31/135, A61K 9/00

Agent:

Stephen Garner, Mathys & Squire LLP

Status:

█ GRANT OF PATENT INTENDED

GLUCOSYLCERAMIDE SYNTHASE INHIBITORS

IPC classification:

A61K 31/439, C07D 471/08, C07D 453/02, A61P 35/00, A61P 25/00

Applicant:

Genzyme Corporation

Agent:

Stephen Garner, Mathys & Squire LLP

Status:

█ GRANT OF PATENT INTENDED

BIOGLASS WITH GLYCOSAMINOGLYCANS

IPC classification:

A61K 33/04, A61K 9/14, A61F 13/00

Agent:

Multiple attorneys, Mathys & Squire LLP

Status:

█ GRANT OF PATENT INTENDED

COMPOSITIONS AND METHODS FOR TREATING PROTEINOPATHIES

IPC classification:

A61K 38/46, A61P 25/28

Applicant:

Genzyme Corporation

Agent:

Stephen Garner, Mathys & Squire LLP

Status:

█ EXAMINATION IN PROGRESS

IL-6 ANTAGONISTS AND USES THEREOF

IPC classification:

C07K 16/24, A61P 27/02

Agent:

Vossius & Partner Patentanwälte Rechtsanwälte mbB

Agent:

Multiple attorneys, Mathys & Squire LLP

Status:

█ EXAMINATION IN PROGRESS

BIOACTIVE GLASS WITH ETHYLENE OXIDE PROPYLENE OXIDE BLOCK COPOLYMERS

IPC classification:

A61F 2/28

Agent:

Multiple attorneys, Mathys & Squire LLP

Status:

█ GRANT OF PATENT INTENDED

SOLID COMPOSITIONS

IPC classification:

A61K 31/00, A61K 9/20, A61K 9/16, A61K 9/14

Applicant:

AbbVie Bahamas Limited

Agent:

Stephen Garner, Mathys & Squire LLP

Agent:

Micaela Modiano, Modiano & Partners

Status:

█ EXAMINATION REQUESTED

SALT FORMS OF (S)-QUINUCLIDIN-3-YL (2-(2-(4-FLUOROPHENYL)THIAZOL-4-YL)PROPAN-2-YL)CARBAMATE

IPC classification:

A61P 3/00, A61P 35/00, A61K 31/439, C07D 453/00

Applicant:

Genzyme Corporation

Agent:

Stephen Garner, Mathys & Squire LLP

Status:

█ EXAMINATION IN PROGRESS

PIPERAZINE DERIVATIVES AND THEIR USE AS KIT MODULATORS

IPC classification:

A61P 17/00, A61K 31/5377, A61K 31/517, C07D 487/04, C07D 239/94, C07D 409/14, C07D 403/14, C07D 403/04, C07D 401/12, C07D 413/14, C07D 405/14

Agent:

Stephen Garner, Mathys & Squire LLP

Status:

█ EXAMINATION IN PROGRESS

SODIUM CONTAINING SOL-GEL DERIVED BIOACTIVE GLASSES AND USES THEREOF INCLUDING HEMOSTASIS

IPC classification:

C08K 9/06, C03C 3/078

Agent:

Multiple attorneys, Mathys & Squire LLP

Status:

█ EXAMINATION REQUESTED

CHIMERIC CYTOKINE FORMULATIONS FOR OCULAR DELIVERY

IPC classification:

A61K 47/26, A61K 47/10, A61K 9/00, A61K 38/20

Agent:

Multiple attorneys, Mathys & Squire LLP

Status:

█ EXAMINATION REQUESTED

COMPOSITIONS AND METHODS FOR MANUFACTURING SOL-GEL DERIVED BIOACTIVE BOROPHOSPHATE GLASSES FOR MEDICAL APPLICATONS

IPC classification:

C08K 9/06, C03C 3/078

Agent:

Multiple attorneys, Mathys & Squire LLP

Status:

█ EXAMINATION REQUESTED

METHOD OF PREPARING GLUCOSYLCERAMIDE SYNTHASE INHIBITORS

IPC classification:

C07D 277/30, C07D 417/06, C07D 453/02

Applicant:

Genzyme Corporation

Agent:

Stephen Garner, Mathys & Squire LLP

Status:

█ EXAMINATION IN PROGRESS

ALBUMIN VARIANTS BINDING TO FCRN

IPC classification:

G01N 33/50

Agent:

Stephen Garner, Mathys & Squire LLP

Agent:

Rachel Clare Williams, Novozymes Biopharma UK Limited

Status:

█ EXAMINATION IN PROGRESS

PYRIDAZINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING COGNITIVE IMPAIRMENT

IPC classification:

A61K 31/50

Agent:

Stephen Garner, Mathys & Squire LLP

Status:

█ The patent has been granted

COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT

IPC classification:

A61K 31/53, A61P 35/00, C07D 487/04

Agent:

Stephen Garner, Mathys & Squire LLP

Status:

█ GRANT OF PATENT INTENDED

INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR

IPC classification:

A61P 35/00, A61K 31/498, C07D 409/12, C07D 403/14, C07D 405/12, C07D 235/30, C07D 401/12, C07D 401/04, C07D 403/12

Agent:

Stephen Garner, Mathys & Squire LLP

Status:

█ EXAMINATION REQUESTED

SOLID PHARMACEUTICAL COMPOSITIONS USEFUL IN HCV TREATMENT

IPC classification:

A61P 31/22, A61K 31/497, A61K 31/4025, A61K 31/427, A61K 9/20, A61K 9/14, A61K 47/32, A61K 47/22, A61K 47/14, A61K 9/00

Applicant:

AbbVie Deutschland GmbH & Co KG

Agent:

Stephen Garner, Mathys & Squire LLP

Agent:

Micaela Modiano, Modiano & Partners

Status:

█ EXAMINATION REQUESTED

GLUCOSYLCERAMIDE SYNTHASE INHIBITORS

IPC classification:

A61P 9/00, A61K 31/439

Applicant:

Genzyme Corporation

Agent:

Stephen Garner, Mathys & Squire LLP

Status:

█ EXAMINATION IN PROGRESS

SOLID ANTIVIRAL DOSAGE FORMS

IPC classification:

A61P 31/14, A61K 31/513, A61K 31/497, A61K 31/427, A61K 31/4025, A61K 9/24, A61K 47/38, A61K 47/32

Applicant:

AbbVie Deutschland GmbH & Co KG

Agent:

Stephen Garner, Mathys & Squire LLP

Agent:

Micaela Modiano, Modiano & Partners

Status:

█ EXAMINATION REQUESTED

SITE-SPECIFIC GLYCOENGINEERING OF TARGETING MOIETIES

IPC classification:

C07K 16/40, C07K 16/32, C07K 16/28, A61K 47/60

Applicant:

Genzyme Corporation

Agent:

Stephen Garner, Mathys & Squire LLP

Status:

█ EXAMINATION REQUESTED

CRYSTAL FORMS

IPC classification:

A61P 31/14, A61K 38/05, A61K 31/4178, C07D 519/00, C07D 417/14, C07D 413/14, C07D 405/14, C07D 403/14, C07D 401/10, C07D 207/16

Applicant:

AbbVie Inc

Agent:

Stephen Garner, Mathys & Squire LLP

Agent:

Micaela Modiano, Modiano & Partners

Status:

█ EXAMINATION REQUESTED

ELIGLUSTAT (GENZ 112638) AS INHIBITOR OF GLUCOSYLCERAMIDE SYNTHASE FOR USE IN A METHOD OF TREATING FABRY'S OR GAUCHER'S DISEASE, THE METHOD COMPRISING ADJUSTING THE INDIVIDUAL THERAPEUTICAL DOSE TO THE P-450 METABOLISM OF THE PATIENT

IPC classification:

A61P 35/00, A61K 31/4025, A61K 45/06, C07D 405/06

Applicant:

Genzyme Corporation

Agent:

Stephen Garner, Mathys & Squire LLP

Status:

█ EXAMINATION IN PROGRESS

NAMPT INHIBITORS AND METHODS

IPC classification:

A61P 37/06, A61P 35/00, A61P 31/12, A61K 31/537, A61K 31/444, A61K 31/438, C07D 498/10, C07D 491/20, C07D 491/107

Agent:

Stephen Garner, Mathys & Squire LLP

Status:

█ EXAMINATION REQUESTED

CRYSTAL FORMS

IPC classification:

A61K 38/12

Agent:

Stephen Garner, Mathys & Squire LLP

Agent:

Micaela Modiano, Modiano & Partners

Status:

█ EXAMINATION REQUESTED

EUTECTIC FORMULATIONS OF CYCLOBENZAPRINE HYDROCHLORIDE

IPC classification:

A61P 21/02, A61K 31/047, A61K 31/135

Agent:

Stephen Garner, Mathys & Squire LLP

Status:

█ Request for examination was made

METHODS OF TREATING MUCOPOLYSACCHARIDOSIS IIIB (MPSIIIB)

IPC classification:

C12N 9/24, A61K 38/47

Agent:

Stephen Garner, Mathys & Squire LLP

Status:

█ Request for examination was made

LYSOSOMAL STORAGE DISEASE ENZYME

IPC classification:

A61K 38/38, C12N 9/20, A61K 31/194, A01K 67/027, A61P 3/06, A61K 31/135, A61K 31/397, A61K 31/366, A61K 38/46

Agent:

Stephen Garner, Mathys & Squire LLP

Status:

█ The application has been published

CARBIDOPA AND L-DOPA PRODRUGS AND THEIR USE TO TREAT PARKINSON'S DISEASE

IPC classification:

A61P 25/16, A61K 31/6615, A61K 31/661

Applicant:

AbbVie Inc

Agent:

Stephen Garner, Mathys & Squire LLP

Status:

█ Request for examination was made

LEVODOPA AND CARBIDOPA INTESTINAL GEL AND METHODS OF USE

IPC classification:

A61K 31/198, A61K 31/195, A61K 47/38, A61K 9/10, A61K 9/00

Applicant:

AbbVie Inc

Agent:

Stephen Garner, Mathys & Squire LLP

Status:

█ Request for examination was made

METHODS FOR TREATING PROTEINOPATHIES

IPC classification:

A61P 25/28, A61P 25/16, A61K 31/439, A61K 31/00

Agent:

Stephen Garner, Mathys & Squire LLP

Status:

█ Request for examination was made

BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT

IPC classification:

A61P 25/00, A61K 31/5513, C07D 487/14

Agent:

Stephen Garner, Mathys & Squire LLP

Status:

█ Request for examination was made

SOLID PHARMACEUTICAL COMPOSITIONS FOR TREATING HCV

IPC classification:

A61P 31/14, A61K 31/498, A61K 31/454, A61K 9/24, A61K 9/20, A61K 9/14

Applicant:

AbbVie Inc

Agent:

Stephen Garner, Mathys & Squire LLP

Status:

█ Request for examination was made

COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO KIT AND PDGFR

IPC classification:

A61P 35/00, A61K 31/53, C07D 487/04

Agent:

Stephen Garner, Mathys & Squire LLP

Status:

█ Request for examination was made

SOLID PHARMACEUTICAL COMPOSITIONS FOR TREATING HCV

IPC classification:

A61P 31/14, A61K 31/498, A61K 31/454, A61K 9/24, A61K 9/20, A61K 9/14

Applicant:

AbbVie Inc

Agent:

Stephen Garner, Mathys & Squire LLP

Status:

█ Request for examination was made

COMPOUNDS AND COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO NTRK

IPC classification:

A61P 35/00, A61K 31/519, C07D 487/04

Agent:

Stephen Garner, Mathys & Squire LLP

Status:

█ Request for examination was made

ANTI-VIRAL TETRAHYDROFURANE DERIVATIVES

IPC classification:

A61K 31/7072, A61P 31/14, C07H 19/06

Applicant:

AbbVie Inc

Agent:

Stephen Garner, Mathys & Squire LLP

Status:

█ Request for examination was made

SOLID PHARMACEUTICAL DOSAGE FORM COMPRISING AN HIV PROTEASE INHIBITOR SOLID DISPERSION

IPC classification:

A61K 31/425, A61K 9/20, A61K 9/14

Applicant:

AbbVie Inc

Agent:

Stephen Garner, Mathys & Squire LLP

Status:

█ The application has been published

WNT SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF

IPC classification:

A61P 43/00, A61K 31/444, A61K 31/4725

Agent:

Stephen Garner, Mathys & Squire LLP

Status:

█ Request for examination was made

INHIBITORS OF RET

IPC classification:

A61K 31/4439, A61K 31/506, A61K 31/53, A61P 35/00, C07D 403/14, C07D 401/14

Agent:

Stephen Garner, Mathys & Squire LLP

Status:

█ Request for examination was made